Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
| 43.96 | |
| 44.22 | |
| - | |
| 44.44 | |
| 43.495 | |
| 27.985-50.99 | |
| 3 309 M | |
| 75 469 K | |
| 0 | |
| -0.62 | |
| 1.265 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Key Insights Using the 2 Stage Free Cash Flow to Equity, Xenon Pharmaceuticals fair value estimate is US$55.22 Current share price of US$41.90 suggests Xenon Pharmaceuticals is potentially 24% underv...
Longboard Pharmaceuticals LBPH gained 14.4% on Jul 1 after it announced that the FDA has granted Breakthrough Therapy designation for its investigational drug, bexicaserin, to treat seizures associat...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
